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Abstract
Zonulin is the only physiological mediator known to regulate intestinal permeability reversibly by modulating intercellular
tight junctions. To investigate the relationship between intestinal permeability and obesity-associated metabolic
disturbances in humans, we aimed to study circulating zonulin according to obesity and insulin resistance. Circulating
zonulin (ELISA) was measured in 123 caucasian men in association with inflammatory and metabolic parameters (including
minimal model-measured insulin sensitivity). Circulating zonulin increased with body mass index (BMI), waist to hip ratio
(WHR), fasting insulin, fasting triglycerides, uric acid and IL-6, and negatively correlated with HDL-cholesterol and insulin
sensitivity. In multiple regression analysis, insulin sensitivity (p=0.002) contributed independently to circulating zonulin
variance, after controlling for the effects of BMI, fasting triglycerides and age. When circulating IL-6 was added to this model,
only BMI (p=0.01) contributed independently to circulating zonulin variance. In conclusion, the relationship between
insulin sensitivity and circulating zonulin might be mediated through the obesity-related circulating IL-6 increase.
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Introduction
Obesity has been associated with increased intestinal perme-
ability and absorption [1]. Obesity is correlated with dramatic
increases in intestinal absorptive capacity by increasing in amounts
of absorptive mucosa [1]. In mice, it has been reported that
intestinal weight, length, and mucosal mass increased significantly
with diabetes [2].
Intestinal permeability regulates molecular trafficking between
the intestinal lumen and the submucosa, leading to either
tolerance or immunity to non–self-antigens [3,4]. The intercellular
tight junctions (TJs) tightly regulate this paracellular antigen
trafficking. TJs are appreciated to be extremely dynamic structures
operative in several key functions of the intestinal epithelium
under both physiological and pathological circumstances [5].
Persistent high circulating levels of inflammatory cytokines, which
are often observed in obese subjects, may be an important
contributor to intestinal barrier dysfunction by altering structure
and localization of TJs [6].
Zonulin is the only physiological mediator known to regulate
intestinal permeability reversibly by modulating intercellular TJs
[7,8]. Human zonulin is a <47-kDa protein that increases
intestinal permeability in small intestine and participates in
intestinal innate immunity. Circulating zonulin in serum is
considered as a useful marker of intestinal permeability [8,9]. In
fact, in humans it has been validated using lactulose/manitol tests,
being serum zonulin strongly correlated with the lactulose/manitol
ratio (or intestinal permeability) [10]. Lactulose/mannitol (La/Ma)
test is currently used in the investigation of intestinal permeability
in several gastrointestinal diseases and malnutrition. This test is
performed by oral administration of two sugar probes followed
by the determination of their amounts excreted in the urine over a
5-h period [11].’’
To gain insight in the relationship between intestinal perme-
ability and obesity-associated metabolic disturbances in humans,
we hypothesized a possible association between circulating
zonulin, obesity and insulin sensitivity according to glucose
tolerance.
Methods
Participants’ Recruitment and Anthropometric
Measurements
One hundred twenty three Caucasian men were recruited and
studied in ongoing study dealing on non-classical cardiovascular
risk factors in Northern Spain. Subjects were randomly localized
from a census and they were invited to participate. The
participation rate was 71%. A 75 g oral glucose tolerance test
according to the American Diabetes Association Criteria was
performed in all subjects. All subjects with normal glucose
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hour post-load plasma glucose ,7.8 mM after a 75 g oral glucose
tolerance test. Glucose intolerance was diagnosed in 41 subjects
according to the American Diabetes Association Criteria (post-
load glucose between 7.8 and 11.1 mmol/l). Inclusion criteria
included the following: 1) BMI ,40 kg/m
2, 2) absence of systemic
disease, and 3) absence of infection within the previous month.
None of the control subjects were under medication or had
evidence of metabolic disease other than obesity. Alcohol and
caffeine were withheld within 12 h of performing the insulin
sensitivity test. Liver disease and thyroid dysfunction were
specifically excluded by biochemical work-up. All subjects gave
written informed consent after the purpose of the study was
explained to them. The ethical committee of the Hospital
Universitari Dr. Josep Trueta (Comite ` d’E `tica d’Investigacio ´
Clı ´nica, CEIC) approved the protocol.
Subjects were studied in the post-absorptive state. BMI was
calculated as weight (in kilograms) divided by height (in meters)
squared. Subjects’ waists were measured with a soft tape midway
between the lowest rib and the iliac crest; hip circumference was
measured at the widest part of the gluteal region; and waist-to-hip
ratio (WHR) was accordingly calculated.
Study of Insulin Sensitivity
Insulin sensitivity was measured using the frequently sampled
intravenous glucose tolerance test (FSIVGTT). In brief, basal
Table 1. Anthropometrical and biochemical parameters from
the participants of the study.
NGT GI P
N 82 41
Age (years) 48.29611.7 55.9610.3 0.001
BMI (Kg/m
2) 26.663.2 28.163.8 0.03
WHR 0.92960.064 0.95260.069 0.06
Fasting glucose (mg/dl) 92.967.3 101.15610.47 ,0.0001
Fasting insulin (mg/dl) 8.163.6 11.166.5 0.01
HbA1c (%) 4.7860.32 4.960.42 0.1
Log IS (10
24/min
21?mU
per liter)
0.5860.2 0.4360.16 ,0.0001
HDL-Cholesterol (mg/dl) 52.8612.9 52.2610.1 0.8
Fasting triglycerides (mg/dl) 83 (58.5–120.5) 100 (69.5–129) 0.5
Uric acid (mg/dl) 5.6361.3 6.1261.4 0.05
Circulating IL-6 (pg/ml) 1.2261.1 1.3760.9 0.4
Zonulin (ng/ml) 9.164.5 10.964.8 0.03
NGT, participants with normal glucose tolerance; GI, participants with glucose
intolerance; WHR, waist to hip ratio; HbA1c, Glycosylated haemoglobin; IS,
insulin sensitivity.
doi:10.1371/journal.pone.0037160.t001
Figure 1. The correlation between insulin sensitivity and circulating zonulin in participants with normal glucose tolerance (NGT,
n=82) and with glucose intolerance (GI, n=41).
doi:10.1371/journal.pone.0037160.g001
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(300 mg/kg body wt) was injected over 1 min starting at time 0. At
20 min, regular insulin (Actrapid, Novo, Denmark; 0.03 U/kg)
was injected as a bolus. Additional samples were obtained from a
contralateral antecubital vein at times 1, 2, 3, 4, 5, 6, 7, 8, 10, 12,
14, 16, 19, 20, 22, 23, 24, 25, 27, 30, 40, 50, 60,70, 80, 90, 100,
120, 140, 160, and 180 min. Samples were rapidly collected via a
three-way stopcock connected to the butterfly needle. Data from
the FSIVGTT were submitted to computer programs that
calculate the characteristic metabolic parameters by fitting glucose
and insulin to the minimal model that describes the times course of
glucose and insulin concentrations. The glucose disappearance
model, by accounting for the effect of insulin and glucose on
glucose disappearance, provides the parameters SI (10
24) per
minute per microunit per milliliter) or the insulin sensitivity index,
a measure of the effect of insulin concentrations above the basal
level to enhance glucose disappearance. The estimation of model
parameters was performed according to the MINMOD computer
program [12].
Analytical Methods
Serum glucose concentrations were measured in duplicate by
the glucose oxidase method using a Beckman glucose analyzer II
(Beckman Instruments, Brea, California). Glycosylated haemoglo-
bin (HbA1c) was measured by the high-performance liquid
chromatography method (Bio-Rad, Muenchen, Germany, and
autoanalyser Jokoh HS-10, respectively). Intraassay and interassay
coefficients of variation were less than 4% for all these tests. Serum
insulin was measured in duplicate by monoclonal immunoradio-
metric assay (Medgenix Diagnostics, Fleunes, Belgium). The intra-
assay coefficient of variation was 5.2% at a concentration of
10 mU/l and 3.4% at 130 mU/l. The interassay coefficients of
variation were 6.9 and 4.5% at 14 and 89 mU/l, respectively.
Total serum triglycerides were measured through the reaction of
glycerol-phosphate-oxidase and peroxidase on a Hitachi 917
instrument (Roche, Mannheim, Germany). HDL cholesterol was
quantified after precipitation with polyethylene glycol at room
temperature. Total serum triglycerides were measured through the
reaction of glycerol/phosphate/oxidase and peroxidase. Uric acid
was determined by routine laboratory tests. Serum zonulin
concentrations were measured by zonulin ELISA Kit (K5600,
Immundiagnostik AG, Bensheim, Germany). Intra- and interassay
coefficients of variation for these determinations were between 3–
7% and between 5–12%, respectively. The ELISA kit used for
zonulin measurement only detects the active (uncleaved) form of
zonulin. Serum IL-6 concentrations were measured using a solid-
phase, enzyme-labeled, chemiluminescent sequential immuno-
metric assay (Immulite 2000; DPC DIPESA S.A., Madrid,
Spain). Analytical intra-assay sensitivity was 0.5 pg/ml. No
cross-reactivity with other cytokines was evident. Serum samples
were diluted and assayed according to the manufacturer’s
instructions. Intra- and interassay coefficients of variation for IL-
6 determinations were between 5–10%.
Statistical Analysis
Statistical analyses were performed using SPSS 12.0 software.
Unless otherwise stated, descriptive results of continuous variables
are expressed as mean and SD for Gaussian variables. Parameters
that did not fulfill normal distribution were mathematically
transformed to improve symmetry for subsequent analyses. The
relation between variables was analyzed by simple correlation
(Pearson’s test) and multiple regression analyses. Unpaired t tests
were used to compare subjects with NGT and AGT subjects.
Levels of statistical significance were set at P,0.05.
Results
In all subjects, as a whole circulating zonulin was significantly
increased in obese (n=33) versus non-obese (n=90) subjects
(12.564.6 vs. 9.365.1, p=0.007) and in subjects with glucose
intolerance (10.964.8 vs. 9.164.5, p=0.03) (Table 1). Circulating
zonulin increased with body mass index (BMI), waist to hip ratio
(WHR), fasting insulin, fasting triglycerides, uric acid and IL-6,
and was negatively associated with HDL-cholesterol and insulin
sensitivity (Figure 1) (Table 2).
The associations of circulating zonulin with metabolic variables
according to glucose tolerance are described in Table 2.
In multiple regression analysis, insulin sensitivity (p=0.002)
contributed independently to circulating zonulin variance, after
controlling for the effects of BMI, fasting triglycerides and age
(Table 3). When circulating IL-6 was added to this model, only
BMI (p=0.01) contributed independently to circulating zonulin
variance (Table 3).
Discussion
To the best of our knowledge, this is the first study that associates
circulating zonulin concentration (a marker and modulator of
intestinal permeability [7–10]) with obesity and insulin resistance.
Circulating zonulin concentration was also associated with obesity-
related metabolic disturbances. After performing multiple linear
regression analysis, insulin sensitivity was the main contributor to
circulating zonulin variance, but this association was no longer
significant after controlling for circulating IL-6. The relationship
betweeninsulinsensitivityandcirculatingzonulinmightbemediated
through the obesity-related circulating IL-6 increase [13]. In fact,
supportingthisobservation,zonulingenehasbeenrecentlyreported
Table 2. Pearson’s correlation among circulating zonulin and
metabolic parameter.
All
participants
(N=123)
NGT
(N=82)
GI
(N=41)
rp rp rp
Age (years) 0.18 0.05 0.22 0.045 20.03 0.8
BMI (Kg/m
2) 0.28 0.002 0.16 0.1 0.42 0.007
WHR 0.2 0.025 0.18 0.1 0.17 0.2
Fasting glucose (mg/dl) 20.01 0.9 20.03 0.7 20.11 0.4
Fasting insulin (mg/dl) 0.37
,0.0001 0.18 0.1 0.57
,0.0001
HbA1c (%) 0.14 0.1 0.24 0.03 20.04 0.8
Log IS (10
24/min
21?mU
per liter)
20.28 0.002 20.22 0.045 20.36 0.02
HDL-Cholesterol (mg/dl) 20.21 0.02 20.27 0.01 20.04 0.8
Log Fasting triglycerides
(mg/dl)
0.21 0.02 0.22 0.045 0.15 0.35
Uric acid (mg/dl) 0.2 0.025 0.24 0.03 0.01 0.9
Circulating IL-6 (pg/ml) 0.29 0.008 0.31 0.01 0.22 0.2
NGT, participants with normal glucose tolerance; GI, participants with glucose
intolerance; WHR, waist to hip ratio; HbA1c, Glycosylated haemoglobin; IS,
insulin sensitivity.
doi:10.1371/journal.pone.0037160.t002
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6 control through STAT3 activation and miR-18a induction [15].
Recent evidence suggests a possible role of gut in obesity.
Recent findings emphasize the important symbiotic contributions
(in diversity and function) to the human metabolism made by the
collection of microbial genomes known as the microbiome [16].
Metabolic activities from human gut microbiota correspond to an
extra organ equivalent to the liver [17]. Human gut microbiota
protects the host against pathogenic microbes by establishing a
competitive barrier to their invasion of the mucosal surface, by
strengthening the impermeability of the epithelium and by
stimulating the development and maintaining the state of alert
of the innate and adaptive immune systems [18]. Several studies
have shown that high fat diet altered gut microbiote and intestinal
permeability promoting metabolic disturbances [19,20]. Accord-
ing to these studies, the increased inflammation in small intestine
associated to obesity and metabolic disturbances may lead to
increased in intestinal permeability.
In subjects with glucose intolerance, circulating zonulin was
strongly associated with insulin resistance and obesity. Otherwise,
in subjects with normal glucose tolerance (NGT), zonulin
concentrations were also associated with high levels of uric acid,
HbA1c, circulating IL-6 and low HDL-Cholesterol. In conclusion,
circulating zonulin might help us to know the contribution of small
intestine permeability on glucose intolerance and insulin resis-
tance. Functional ex-vivo studies with recombinant zonulin in
mouse intestinal segments have shown that zonulin increased
significantly intestinal permeability [14]. The increased zonulin
concentration might exert negative effects on intestinal perme-
ability leading to obesity- and insulin resistance-related metabolic
disturbances. Further studies are necessary to investigate the
possible contribution of zonulin-associated loss of intestinal barrier
function on these metabolic disturbances.
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